Is the ResMed share price in the buy zone ahead of next week's update?

This sleep treatment company's eagerly anticipated Q2 update is coming next week.

| More on:
A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a tough 12 months for the ResMed Inc. (ASX: RMD) share price.

Despite recovering strongly since hitting a 52-week low of $21.14 in September, the sleep treatment company's shares are still down 20% on an annual basis.

This has been driven by concerns over the impact of GLP-1 drugs like Ozempic on its addressable market.

But with many analysts saying that these drugs are not a threat, should investors be snapping up ResMed's shares before the release of its second quarter update next week?

Is the ResMed share price good value?

The team at Citi has been looking at the company ahead of its results release.

According to the note, the broker is expecting double-digit revenue growth for the second quarter. This is expected to be driven by solid performances across devices, masks, and software.

As a result, it sees a lot of value in its shares and has put a buy rating and $29.00 price target on them.

Based on the current ResMed share price of $26.00, this implies potential upside of 11.5% for investors over the next 12 months.

Over at Goldman Sachs, its analysts agree and are recommending the company as a buy.

The broker is even more positive, though, with its buy rating and $32.00 price target. This suggests a return of 23% for investors from current levels.

Its analysts are not concerned by the threat of GLP-1 drugs and believe investors should be snapping up its shares while they are cheap. The broker said:

[W]e believe the perceived downside risk from GLP-1/GIPs has been over-capitalised at RMD's current valuation. Overall, we reduce our TP -3% (with our earnings upgrades offset by mark to market multiples today), and continue to see asymmetric upside risk from current levels and reiterate our Buy rating.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »